Why AbbVie’s former president has high hopes for this Flagship-backed biotech

Why AbbVie’s former president has high hopes for this Flagship-backed biotech

Source: 
Pharma Voice
snippet: 

The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.